Myeloma
If it’s your first time on this website, please read the disclaimer section.
Jul 20 – Jul 27, 2026
International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This International Myeloma Working Group recommendation provides updated guidelines for the diagnosis, evaluation, treatment, and response assessment of solitary plasmacytomas (SPs), rare localized tumors of clonal plasma cells. It highlights that approximately 50% of SPs progress to symptomatic myeloma within 5 years, necessitating careful exclusion of multiple myeloma using advanced diagnostics. Local radiotherapy is the mainstay therapy, with systemic therapy’s benefit remaining poorly defined. These recommendations offer crucial guidance for clinicians managing this cancer, emphasizing accurate diagnosis and follow-up given the significant progression risk.
10.1200/JCO-26-00410
Jul 13 – Jul 20, 2026
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This phase 2 trial evaluated the safety and efficacy of teclistamab-based induction regimens (Tec-DR or Tec-DVR) in 49 transplant-eligible patients with newly diagnosed multiple myeloma. Results demonstrated a 100% overall response rate and a 91.8% MRD-negative complete response rate by the premaintenance timepoint, with 100% MRD negativity achieved in all evaluable samples at cycle 6. While grade 3/4 adverse events occurred in 91.8% of patients—primarily hematologic toxicities—cytokine release syndrome was limited to grade 1 or 2 (67.3%) and no neurotoxicity was reported. These findings suggest that teclistamab-based induction is a highly effective and feasible strategy for achieving deep molecular responses in frontline myeloma treatment before stem cell transplantation.
10.1038/s41591-026-04471-x
Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.
NEW ENGL J MED · Q1 JOURNAL - RANK #2/332TOP-TIER
This phase 3 trial (ENDURANCE) randomized 516 patients with standard-risk newly diagnosed multiple myeloma to continuous lenalidomide maintenance versus 2-year fixed-duration therapy after induction. At median 86-month follow-up, overall survival at 7 years was nearly identical: 68.6% continuous vs 69.0% fixed (difference -0.4%, P=0.93). Progression-free survival at 7 years was 36.1% vs 29.7% (difference 6.4%, 95% CI -2.6 to 15.4), but continuous therapy increased grade ≥3 nonhematologic adverse events (48.2% vs 31.5%) and 5-year second primary cancer incidence (11.2% vs 8.3%). For clinicians managing multiple myeloma, indefinite maintenance did not improve survival but added toxicity and cancer risk, supporting a 2-year fixed duration for standard-risk patients not undergoing transplant.
10.1056/NEJMoa2600157
Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This population-based screening study and randomized trial in Iceland (n=75,422) investigated the benefits and harms of screening for monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma (MM). Screening led to a 27-fold increase in smoldering MM detection (8.6% vs 0.3%; HR 27.46) and diagnosed active MM and related malignancies 1 year earlier in intervention arms, with fewer symptomatic presentations. Importantly, MGUS notification was not associated with adverse psychological outcomes, demonstrating earlier cancer detection without psychological harm. These findings suggest population-based screening facilitates earlier MM diagnosis and access to early intervention, though long-term survival and cost-effectiveness require further investigation.
10.1200/JCO-25-02771
Jun 15 – Jun 22, 2026
Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This systematic review and meta-analysis of 20 studies (2,551 patients) estimated the frequency of second primary malignant neoplasms (SPMs) after T-cell-engaging bispecific antibody (BsAb) therapy for B-cell non-Hodgkin lymphoma and multiple myeloma. At a median follow-up of 17.4 months, the pooled proportion of total SPMs was 3.5% (95% CI, 1.8-6.9), with 2.2% leading to treatment discontinuation and 1.4% to death. For clinicians managing cancer patients, these results quantify a measurable, clinically relevant long-term complication of a novel immunotherapy class now moving into earlier treatment lines. The findings underscore the need for standardized, extended safety surveillance and careful risk-benefit counseling when considering BsAb therapy.
10.1001/jamaoncol.2026.1859
Jun 08 – Jun 15, 2026
Systemic amyloid light-chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates.
CA-CANCER J CLIN · Q1 JOURNAL - RANK #1/326TOP-TIER
This review examines the evolving diagnostic and therapeutic landscape of systemic light-chain (AL) amyloidosis, a life-threatening plasma cell malignancy. It highlights how daratumumab-based frontline regimens have transformed standard care, alongside the integration of cytogenetic profiling and measurable residual disease assessment for risk-adapted management. The analysis covers emerging oncological interventions including BCL-2 inhibitors, bispecific antibodies, and CAR T-cell therapies targeting the underlying monoclonal plasma cell clone. These updates provide clinicians with practical diagnostic algorithms and evidence-based strategies to achieve durable organ recovery and improved survival outcomes.
10.3322/caac.70092
May 18 – May 25, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase III GMMG-HD7 trial evaluated MALDI-TOF mass spectrometry (MS) for minimally invasive detection of monoclonal proteins in 617 patients with newly diagnosed multiple myeloma. MS demonstrated superior sensitivity over serum protein electrophoresis and provided strong prognostic value, with MS negativity at 12 months of maintenance significantly improving progression-free survival (HR 0.25; 95% CI, 0.15–0.43). The study highlights that combining serum MS with bone marrow measurable residual disease (MRD) assessments refines risk stratification and identifies patients at highest risk for relapse. These findings support integrating MS as a reproducible, practical biomarker for longitudinal cancer monitoring and potential risk-adapted treatment strategies in clinical practice.
10.1200/JCO-25-02957
Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This abstract describes the ASCO Living Guideline for the Treatment of Multiple Myeloma, a specific cancer. These guidelines are developed by a standing expert panel through continuous systematic review of rapidly evolving evidence to provide updated clinical practice recommendations. The abstract outlines the methodology and purpose of these dynamic guidelines, emphasizing their regular updates and their role as a continuously evolving resource. While not presenting specific clinical findings, it highlights the importance of evidence-based, frequently updated guidance for cancer treatment, reminding clinicians that guidelines supplement, not replace, professional judgment.
10.1200/JCO-26-01139
Apr 27 – May 04, 2026
Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This randomized, placebo-controlled trial evaluated whether prophylactic B-cell depletion with obinutuzumab could prevent corticosteroid-requiring chronic graft-versus-host disease (cGVHD) in 178 allogeneic transplant recipients. Obinutuzumab significantly reduced the 1-year incidence of steroid-requiring cGVHD to 13.3% compared to 35.2% in the placebo group (p=0.0005) and improved 2-year immunosuppression-free, relapse-free survival (48% vs. 34%). While the study focuses on a post-transplant complication, the findings are highly relevant for clinicians managing hematologic malignancies where cGVHD remains a major barrier to successful recovery. These results suggest that early B-cell depletion is an effective strategy for reducing morbidity and improving long-term outcomes in high-risk cancer patients undergoing transplantation.
10.1200/JCO-25-03104
Apr 20 – Apr 27, 2026
Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This expert opinion paper reviews the diagnostic and therapeutic management of various hematologic malignancies diagnosed during pregnancy, addressing the increasing global incidence in this population. The authors evaluate the safety and efficacy of diagnostic modalities and treatment options, including chemotherapy, radiation therapy, and immunotherapy, for conditions such as acute leukemia and lymphomas. It provides clinical guidance on balancing maternal oncological care with fetal safety, emphasizing that more women are now receiving adequate treatment without compromising pregnancy outcomes. The findings suggest that multidisciplinary approaches allow for expanded treatment possibilities, though specific numerical survival data were not provided in this qualitative expert consensus.
10.1200/JCO-25-02351
Identifying High-Risk Smoldering Multiple Myeloma for Early Intervention.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This retrospective cohort study compared two definitions of high-risk smoldering multiple myeloma (SMM) to identify which best predicts progression to active multiple myeloma. Using data from a screened cohort (iStopMM, n=193) and a clinical cohort (DALY-CARE, n=1147), the AQUILA criteria classified 34-55% of patients as high-risk, while the 2/20/20 model identified only 8-19%. The 2/20/20 model captured a higher 2-year progression risk (44.1% vs 27.0%) and annual progression rate (27.3% vs 14.5%), indicating it more accurately isolates truly high-risk patients. The findings directly support using the 2/20/20 model to guide early intervention decisions in SMM, a cancer precursor.
10.1001/jamaoncol.2026.0831